Blair Janis E, Mayer Anita P, Currier Jeremiah, Files Julia A, Wu Qing
Division of Infectious Diseases, Mayo Clinic, Scottsdale, Arizona 85259, USA.
Clin Infect Dis. 2008 Dec 15;47(12):1513-8. doi: 10.1086/593192.
Coccidioidomycosis is a fungal infection acquired via inhalation of airborne fungal arthrospores of Coccidioides species in regions of endemicity in the deserts of the southwestern United States and northern Mexico. In recent years, the incidence of coccidioidomycosis has increased in areas of endemicity, and previous studies have found the highest incidence of coccidioidal infection in Arizona among persons in older age groups.
We conducted a retrospective review of data for all patients with coccidioidomycosis who were treated at our institution that compared clinical manifestations of coccidioidomycosis in patients aged >or=60 years with those in patients aged <60 years.
We compared 210 patients aged >or=60 years with 186 patients aged <60 years. No significant differences were observed with regard to manifestations of coccidioidomycosis, even after adjustment for comorbid conditions, excluding immunosuppression. Regardless of age, when coccidioidal illnesses in immunosuppressed patients were compared with those in nonimmunosuppressed patients, immunosuppressed patients were significantly more likely to have extrapulmonary dissemination of infection, to require hospitalization, and to have progressive infection or to die of coccidioidomycosis. Univariate logistic regression identified immunosuppression as the only marker that increased risk of extrapulmonary dissemination of infection (odds ratio, 2.13;P=.05), hospitalization (odds ratio, 2.68; P<.001), and death (odds ratio, 8.39; P<.001). Multivariate analysis revealed that neither age nor an interaction of age and immunosuppression had a significant impact on coccidioidal manifestations.
Coccidioidomycosis is a serious illness in all patients, but its different manifestations in older-aged persons, compared with those in younger-aged persons, may be related to immunosuppression rather than age alone.
球孢子菌病是一种通过吸入美国西南部沙漠和墨西哥北部流行地区空气中的球孢子菌属真菌关节孢子而获得的真菌感染。近年来,球孢子菌病在流行地区的发病率有所上升,先前的研究发现,亚利桑那州年龄较大人群的球孢子菌感染发病率最高。
我们对在本机构接受治疗的所有球孢子菌病患者的数据进行了回顾性分析,比较了年龄≥60岁患者与年龄<60岁患者的球孢子菌病临床表现。
我们将210例年龄≥60岁的患者与186例年龄<60岁的患者进行了比较。即使在调整合并症(不包括免疫抑制)后,球孢子菌病的表现也未观察到显著差异。无论年龄如何,将免疫抑制患者的球孢子菌病与非免疫抑制患者的球孢子菌病进行比较时,免疫抑制患者更有可能发生肺外播散性感染、需要住院治疗,并且更有可能发生进行性感染或死于球孢子菌病。单因素逻辑回归分析确定免疫抑制是增加肺外播散性感染风险(比值比,2.13;P = 0.05)、住院风险(比值比,2.68;P < 0.001)和死亡风险(比值比,8.39;P < 0.001)的唯一指标。多因素分析显示,年龄以及年龄与免疫抑制的相互作用均未对球孢子菌病表现产生显著影响。
球孢子菌病对所有患者来说都是一种严重疾病,但与年轻患者相比,其在老年患者中的不同表现可能与免疫抑制有关,而不仅仅与年龄有关。